Jump to content

Temocapril: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
added ref
 
(15 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{unreferenced|date=December 2015}}

{{more citations needed|date=January 2021}}


{{Drugbox
{{Drugbox
Line 45: Line 47:
| chemical_formula =
| chemical_formula =
| C=23 | H=28 | N=2 | O=5 | S=2
| C=23 | H=28 | N=2 | O=5 | S=2
| molecular_weight = 476.608 g/mol
| smiles = CCOC(=O)[C@H](CCc1ccccc1)NC2CS[C@@H](CN(C2=O)CC(=O)O)c3cccs3
| smiles = CCOC(=O)[C@H](CCc1ccccc1)NC2CS[C@@H](CN(C2=O)CC(=O)O)c3cccs3
| StdInChI = 1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18?,20-/m0/s1
| StdInChI = 1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18?,20-/m0/s1
Line 51: Line 52:


}}
}}
<!-- Definition and medical uses -->
'''Temocapril''' (also known as ''temocaprilum'' [Latin]; brand name Acecol) is an [[ACE inhibitor]]. It was not approved for use in the [[United States|US]].


It is administered as inactive [[prodrug]], then converted to its active metabolite, temocaprilat.<ref>Yasunari, K., Maeda, K., Nakamura, M., Watanabe, T., Yoshikawa, J., & Asada, A. (2004). Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovascular drug reviews, 22(3), 189–198. https://doi.org/10.1111/j.1527-3466.2004.tb00140.x</ref>
'''Temocapril''' (also known as ''temocaprilum'' [Latin]; brand name Acecol) is an [[ACE inhibitor]]. It was not approved for use in the US.


<!-- Society and culture -->
[[File:Temocaprilat.svg|thumb|left|Temocaprilat — the active metabolite of temocapril]] {{clear left}}
It was patented in 1984 and approved for medical use in 1994.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=469 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA469 |language=en}}</ref>


==References==
==References==
Line 60: Line 64:


{{ACE inhibitors}}
{{ACE inhibitors}}
{{Angiotensin receptor modulators}}


[[Category:ACE inhibitors]]
[[Category:ACE inhibitors]]
Line 68: Line 73:
[[Category:Prodrugs]]
[[Category:Prodrugs]]
[[Category:Thiophenes]]
[[Category:Thiophenes]]
[[Category:Butyrates]]
[[Category:Carboxylate esters]]
[[Category:Nitrogen heterocycles]]
[[Category:Thiazepines]]

[[Category:Sulfur heterocycles]]


{{cardiovascular-drug-stub}}
{{cardiovascular-drug-stub}}
{{stereochemistry-stub}}

Latest revision as of 00:11, 28 January 2024

Temocapril
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 2-[(2S)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H28N2O5S2
Molar mass476.61 g·mol−1
3D model (JSmol)
  • CCOC(=O)[C@H](CCc1ccccc1)NC2CS[C@@H](CN(C2=O)CC(=O)O)c3cccs3
  • InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18?,20-/m0/s1
  • Key:FIQOFIRCTOWDOW-DXCJPMOASA-N
  (verify)

Temocapril (also known as temocaprilum [Latin]; brand name Acecol) is an ACE inhibitor. It was not approved for use in the US.

It is administered as inactive prodrug, then converted to its active metabolite, temocaprilat.[1]

It was patented in 1984 and approved for medical use in 1994.[2]

References

[edit]
  1. ^ Yasunari, K., Maeda, K., Nakamura, M., Watanabe, T., Yoshikawa, J., & Asada, A. (2004). Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovascular drug reviews, 22(3), 189–198. https://doi.org/10.1111/j.1527-3466.2004.tb00140.x
  2. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 469. ISBN 9783527607495.